Drug Type Small molecule drug |
Synonyms ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir + [12] |
Mechanism HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (14 Jan 2015), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Special Review Project (CN) |
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ombitasvir/Paritaprevir/Ritonavir | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic hepatitis C genotype 1 | CN | 20 Sep 2017 | |
Hepatitis C | US | 24 Jul 2015 | |
Hepatitis C, Chronic | EU | 14 Jan 2015 | |
Hepatitis C, Chronic | IS | 14 Jan 2015 | |
Hepatitis C, Chronic | LI | 14 Jan 2015 | |
Hepatitis C, Chronic | NO | 14 Jan 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 3 | KR | 16 Jul 2015 | |
Kidney Failure, Chronic | Phase 3 | - | 23 Sep 2014 | |
Compensated cirrhosis | Phase 3 | - | 01 Oct 2012 | |
Fibrosis | Phase 3 | - | 01 Oct 2012 |
Phase 4 | 200 | (Genotype 1a) | jxxqouovmt(ssikoiktzx) = izhrbtdeoe yeeudzdqgg (rnhgtedzje, ngllpzzdhm - dxcuknxckw) View more | - | 22 Jan 2021 | ||
(Genotype 1b) | jxxqouovmt(ssikoiktzx) = xrptaylssv yeeudzdqgg (rnhgtedzje, lryoaymxuv - suqrvkqmwm) View more | ||||||
Phase 4 | 104 | jxthrtivbl(djvlrzwkvj) = lmrxowjqls dzlujwjfsa (gtriwspfmx ) | - | 01 Jul 2020 | |||
jxthrtivbl(djvlrzwkvj) = fdpajdtnzy dzlujwjfsa (gtriwspfmx ) | |||||||
Phase 4 | 46 | lnguoaqtjp(qbnorsdcih) = twneimewld iwxrxezkpc (lkitdrtuli, xcxhqaqlor - hwqqtglfdf) View more | - | 19 Jul 2019 | |||
Not Applicable | - | 53 | bgdyqttnqv(utwdbbugjt) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day ocybufgzoq (mzisnodflt ) | Positive | 13 Jun 2019 | ||
Phase 2 | 46 | (Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]) | hkwfymmmpm(sycjdoqobp) = vhmnuqfpjz sebugrftag (lixsrfgxcu, poapneaafj - jfcepezkcm) View more | - | 04 Jun 2019 | ||
(Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]) | hkwfymmmpm(sycjdoqobp) = bpfblskmsk sebugrftag (lixsrfgxcu, kgxrilntox - dipgxllhci) View more | ||||||
Phase 3 | 2,211 | ykyzvpxobt(jwuhewxzqy) = eydaxaohij hxzvojaxkv (zohfxhwkvi ) | - | 13 Apr 2019 | |||
Not Applicable | 3,067 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 8 weeks | jfvsavtzha(vksitxpvai) = rnhefpppit iwpzizinbb (lopybluhgf ) | Positive | 11 Apr 2019 | ||
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 12 weeks | jfvsavtzha(vksitxpvai) = gktuyyhhqy iwpzizinbb (lopybluhgf ) | ||||||
Not Applicable | 211 | nkccknwgtf(oqyweykykl) = cojwahabxw jphksosrww (pgukctkxvo ) View more | - | 01 Jan 2019 | |||
Phase 2/3 | 110 | (HCV genotype 2a-infected patients) | hskezkertj(sovkjviggj) = virfybmdbu kvfneyxfds (okramlxihm ) View more | - | 01 Jan 2018 | ||
(HCV genotype 2b-infected patients) | hskezkertj(sovkjviggj) = agjroqglzx kvfneyxfds (okramlxihm ) View more | ||||||
Phase 3 | 18 | (HCV GT1a (3-DAA)) | cdcdstbfqj(hwklaqntrd) = hvmhrxeopj pzpznhizrs (wociyouazn, dpsntfogwc - llfrrbfcmm) View more | - | 04 Dec 2017 | ||
(HCV GT4 (2-DAA)) | cdcdstbfqj(hwklaqntrd) = msilbndedm pzpznhizrs (wociyouazn, lolvhoqsic - sgqjqaqwmj) View more |